irinotecan has been researched along with Carcinoma, Neuroendocrine in 55 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (7.27) | 29.6817 |
| 2010's | 39 (70.91) | 24.3611 |
| 2020's | 12 (21.82) | 2.80 |
| Authors | Studies |
|---|---|
| Abdullah, H; Agrawal, S; Deng, M; Meeker, C; Sreekrishnanilayam, K; Vijayvergia, N; Yeung, HM | 1 |
| Boku, N; Furuse, J; Hiraoka, N; Honma, Y; Ikeda, M; Kataoka, T; Kato, K; Kitagawa, Y; Machida, N; Mizuno, N; Morizane, C; Nomura, S; Okano, N; Okusaka, T; Ozaka, M; Sato, T; Sekine, S; Taniguchi, H; Terashima, M; Ueno, M; Yamaguchi, K | 1 |
| Kashu, N; Kataoka, N; Makimoto, S; Mushiake, Y; Shintani, H; Takami, T; Yamaguchi, T; Yasuda, K | 1 |
| Fukunaga, H; Ichikawa, Y; Kim, HM; Kimura, H; Kondou, S; Matsuo, Y; Morita, S; Murakami, M; Sawada, G; Shirai, S; Takada, A | 1 |
| Bruera, G; Carlei, F; Chiominto, A; Cosenza, P; Di Sibio, A; Giuliani, A; Mastropietro, S; Ricevuto, E; Romano, L; Schietroma, M | 1 |
| Batman, E; Cairns, DA; Cave, J; Chau, I; Craig, Z; Faluyi, O; Howard, H; Hubner, R; Lamarca, A; Mansoor, W; McNamara, MG; Meyer, T; Reed, N; Sarker, D; Sharma, R; Swain, J; Valle, JW; Wadsley, J; Wall, L | 1 |
| Li, J; Lu, M; Peng, Z; Shen, L; Wang, X; Zhang, P; Zhang, X; Zhou, J | 1 |
| Cai, LH; Chen, JP; Fu, WH; Hao, HK; He, QL; Huang, CM; Jiang, LX; Li, E; Li, HL; Li, P; Li, SL; Li, Y; Li, YX; Li, Z; Lin, JP; Lin, JX; Lin, W; Tian, YT; Xie, JW; Xu, YC; Xu, ZK; Xue, FQ; Zhao, G; Zhao, YJ; Zheng, CH; Zhou, XJ; Zhou, YB; Zhu, ZG; Zou, BB | 1 |
| Alifieris, CE; Avgoustou, C; Delis, SG; Griniatsos, J; Nikolaou, M; Panagiotidis, MI; Souferi-Chronopoulou, E; Trafalis, DT | 1 |
| Furuta, T; Hamaya, Y; Ishida, N; Iwaizumi, M; Miura, K; Miyazu, T; Osawa, S; Shinmura, K; Sugimoto, K; Sugimura, H; Suzuki, S; Tamura, S; Tani, S; Yamade, M | 1 |
| Coppo, R; Endo, H; Inoue, M; Kakeya, H; Kamiura, S; Kaneko, K; Kimura, T; Kondo, J; Masuda, M; Onuma, K; Tanaka, M; Ueda, Y; Yoshino, K | 1 |
| Afchain, P; Baudin, E; Desgrippes, R; Hadoux, J; Hautefeuille, V; Lepage, C; Lorgis, V; Monterymard, C; Scoazec, JY; Thuillier, F; Tougeron, D; Walter, T | 1 |
| Andrikou, K; Antonuzzo, L; Bardasi, C; Benatti, S; Bertolini, F; Caputo, F; Casadei-Gardini, A; Cerma, K; Dominici, M; Ferrari, M; Fontana, A; Gelsomino, F; Laffi, A; Lavacchi, D; Luppi, G; Marconcini, R; Rimini, M; Salati, M; Santini, C; Spada, F; Spallanzani, A | 1 |
| Chiba, N; Hikita, K; Kawachi, S; Okihara, M; Ozawa, Y; Sano, T; Takano, K; Tomita, K | 1 |
| Cohen, D; Ghaffaripour, T; Stoner, P | 1 |
| Ando, T; Fujinami, H; Hosokawa, A; Kajiura, S; Matsubara, Y; Mihara, H; Nakata, N; Nanjo, S; Sugiyama, T; Takagi, H; Yoshita, H | 1 |
| Endo, K; Imano, H; Kido, T; Kimura, Y; Morimoto, Y; Saito, R; Sasaki, T; Toda, H; Yoshino, K | 1 |
| Hirayu, N; Imamura, T; Shiota, K; Sou, H; Taketani, S; Taniwaki, S; Uchino, Y | 1 |
| Horimatsu, T; Mishima, M; Miyamoto, S | 1 |
| Boudreaux, JP; Ramirez, RA; Thiagarajan, R; Thomas, KEH; Voros, BA; Woltering, EA | 1 |
| Kawai, S; Nagase, M; Ono, K; Takehana, T; Yamamoto, K | 1 |
| Agaimy, A; Cavallaro, A; Fietkau, R; Golcher, H; Grützmann, R; Lubgan, D; Pavel, M; Schmidt, D; Semrau, S | 1 |
| Ishii, G; Ishikawa, Y; Kenmotsu, H; Nagai, K; Nakajima, R; Niho, S; Noguchi, M; Oshita, F; Sekine, I; Tada, H; Watanabe, S | 1 |
| Gao, J; Gong, JF; Li, J; Li, Y; Lu, M; Lu, ZH; Shen, L; Wang, XC; Zhang, XT; Zhou, J | 1 |
| Honda, R; Inoue, S; Nagashima, K; Ohsaki, Y; Onodera, H; Tanno, S | 1 |
| Asaoka, T; Fujitani, K; Hirao, M; Ikeda, M; Ikenaga, M; Miyamoto, A; Nakamori, S; Sekimoto, M; Takeoka, T; Yamamoto, K | 1 |
| Hakamada, K; Kawasaki, H; Kimura, A; Muroya, T; Nagase, H; Nakai, M; Nakayama, Y; Okano, K; Wajima, N; Yonaiyama, S | 1 |
| Asamura, H; Eba, J; Katayama, H; Kenmotsu, H; Niho, S; Shibata, T; Tamura, T; Tsuboi, M; Watanabe, S; Yamamoto, N | 1 |
| Ishikawa, Y; Ito, T; Kenmotsu, H; Kubota, K; Nagai, K; Niho, S; Noguchi, M; Oshita, F; Sekine, I; Tada, H; Watanabe, S; Yamamoto, N; Yoshimura, M | 1 |
| Boku, N; Furuse, J; Ishido, K; Kasuga, A; Machida, N; Morizane, C; Nishina, T; Okusaka, T; Sudo, K; Takahashi, H; Tobimatsu, K; Yamaguchi, T | 1 |
| Inoue, D; Ishii, H; Kanda, H; Matsuyama, M; Muramatsu, Y; Ozaka, M; Yamada, I | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Okita, N; Okuma, HS; Shimada, Y; Shoji, H; Takashima, A; Yamada, Y | 1 |
| Fukunaga, K; Ikuta, S; Kakuno, A; Morita, M; Murao, S; Sonoda, T; Tani, S; Yamagishi, S; Yamanaka, N | 1 |
| Dropkin, E; Strickler, JH; Strosberg, JR; Zhu, J | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Shimizu, S; Takahashi, H; Ueno, H | 1 |
| Chang, GJ; Crane, CH; Das, P; Feig, BW; Krishnan, S; Minsky, BD; Rashid, A; Skibber, JM; Voong, KR; Wolff, RA; Yao, JC | 1 |
| Asaishi, K; Goto, M; Higuchi, K; Kii, T; Kurisu, Y; Kuwakado, S; Miyamoto, T; Nishitani, H; Shimamoto, F; Terazawa, T | 1 |
| Gress, TM; Rinke, A | 1 |
| Kaiho, T; Miyazaki, M; Nishimura, M; Nomura, S; Okamoto, R; Shinmura, K; Togawa, A; Tsuchiya, S; Yanagisawa, S | 1 |
| Fujita, H; Ichimura, K; Ikeda, H; Katoh, H; Kawai, Y; Kodera, M; Maejima, R; Oishi, M; Seshimo, K; Shibagaki, K; Takita, K; Tanaka, N; Toshima, T; Yamamura, M; Yamashita, Y; Yokomichi, N | 1 |
| Fujiwara, H; Ichikawa, D; Ikoma, H; Kikuchi, S; Kokuba, Y; Komiyama, S; Kubota, T; Nakanishi, M; Ochiai, T; Otsuji, E; Sakakura, C; Sonoyama, T | 1 |
| Fukushima, M; Hata, M; Ichikawa, C; Kirii, Y; Miyairi, J; Miyamoto, M; Ota, H; Takagi, H | 1 |
| Haga, T; Kitamura, A; Kuroda, F; Nakajima, Y; Takiguchi, Y; Tatsumi, K | 1 |
| Iwase, Y; Maitani, Y | 2 |
| Hamaguchi, T; Hirashima, Y; Kato, K; Matsubara, J; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Taniguchi, H; Yamada, Y | 1 |
| Grigull, L; Hartmann, C; Linderkamp, C; Reinhardt, D; Sander, A; Schmid, H; Weinel, P; Welte, K | 1 |
| Iwanaga, T; Iwasaki, Y; Maeda, Y; Ohashi, M; Ohinata, R; Omuro, Y; Onoyama, H; Sasaki, E; Shimoyama, T; Tateishi, Y | 1 |
| Kenmotsu, Y; Kondo, T; Murakami, S; Oshita, F; Saito, H; Sugiura, M; Yamada, K | 1 |
| Hatake, K; Ishikawa, Y; Mishima, Y; Nakano, K; Nishimura, N; Sakajiri, S; Takahashi, S; Tsuyama, N; Yokoyama, M; Yuasa, T | 1 |
| Ishikawa, D; Kumagai, M; Mouri, H; Nanjo, S; Ohtsubo, K; Takeuchi, S; Ueda, Y; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Akimoto, Y; Hamasaki, A; Honda, H; Kaneko, M; Okamoto, K; Oshita, T; Takao, Y; Tanimoto, H; Teramoto, H; Teramoto, M | 1 |
| Antonia, S; Chiappori, A; de Lima Lopes, G; Haura, E; Langevin, M; Lush, R; Rocha-Lima, CM; Simon, G; Sullivan, D | 1 |
| Fujiwara, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Tsuta, K; Yamada, K; Yamamoto, N | 1 |
| Araki, T; Fujii, M; Inoue, S; Kimoto, K; Murakami, M; Ohshiro, Y; Oka, K; Tacho, T; Yano, A | 1 |
7 review(s) available for irinotecan and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
[A Case of Long-Term Remission with Surgical Therapy and Chemoradiotherapy for a Rapidly Increasing Large Cell Neuroendocrine Carcinoma(LCNEC)].
Topics: Adult; Carboplatin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemoradiotherapy; Cisplatin; Humans; Irinotecan; Lung; Lung Neoplasms; Male | 2023 |
[Long-Term Survival of a Gastric Neuroendocrine Carcinoma Patient with Extra-Regional Lymph Node Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Recurrence; Stomach Neoplasms; Time Factors | 2017 |
Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Clinical Trials as Topic; Etoposide; Humans; Intestinal Neoplasms; Irinotecan; Neuroendocrine Tumors; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Radiopharmaceuticals; Stomach Neoplasms | 2019 |
[A case of neuroendocrine cell carcinoma of the esophagus with lung metastases successfully treated with CPT-11/CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy | 2013 |
Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Administration Schedule; Etoposide; Everolimus; Humans; Irinotecan; Pancreatic Neoplasms | 2015 |
Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Gastrointestinal Neoplasms; Humans; Irinotecan; Ki-67 Antigen; Neoplasm Grading; Neuroendocrine Tumors; Practice Guidelines as Topic; Prognosis; Treatment Outcome | 2017 |
[A case of gastric neuroendocrine cell carcinoma successfully treated by neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Male; Neoadjuvant Therapy; Stomach Neoplasms | 2011 |
10 trial(s) available for irinotecan and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Digestive System; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2022 |
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Humans; Irinotecan; Leucovorin; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic | 2020 |
Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Etoposide; Humans; Irinotecan; Lung Neoplasms | 2020 |
Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Indazoles; Irinotecan; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Pyrimidines; Sulfonamides | 2020 |
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Neuroendocrine; Etoposide; Female; Fluorouracil; Humans; Intestinal Neoplasms; Irinotecan; Leucovorin; Male; Neoplasm Metastasis; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Progression-Free Survival; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2021 |
Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Small Cell Lung Carcinoma; Survival Rate; Young Adult | 2013 |
A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Clinical Protocols; Disease-Free Survival; Etoposide; Female; Humans; Incidence; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Patient Selection; Survival Analysis; Treatment Outcome | 2014 |
A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Pilot Projects; Pneumonectomy; Young Adult | 2014 |
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2014 |
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2007 |
38 other study(ies) available for irinotecan and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Female; Humans; Irinotecan; Male; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2023 |
[A Case of Rectal Neuroendocrine Carcinoma with Iris Metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Humans; Irinotecan; Iris; Male; Middle Aged; Rectal Neoplasms; Rectum | 2023 |
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an exper
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Neuroendocrine; Fluorouracil; Humans; Irinotecan; Male; Oxaliplatin; Rectal Neoplasms; Rectum; Synaptophysin; Thyroid Nuclear Factor 1; Treatment Outcome | 2019 |
Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Propensity Score; Stomach Neoplasms; Survival Analysis | 2020 |
Tuberous sclerosis patient with neuroendocrine carcinoma of the esophagogastric junction: A case report.
Topics: Carcinoma, Neuroendocrine; Esophagogastric Junction; Female; Humans; Infant, Newborn; Irinotecan; Middle Aged; Stomach Neoplasms; Tuberous Sclerosis | 2020 |
Heterogenous chemosensitivity of a panel of organoid lines derived from small cell neuroendocrine carcinoma of the uterine cervix.
Topics: Antineoplastic Agents; Carboxylic Ester Hydrolases; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Catalysis; Cell Culture Techniques; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Irinotecan; Organoids; Uterine Cervical Neoplasms | 2021 |
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Female; Humans; Irinotecan; Italy; Male; Middle Aged; Neuroendocrine Tumors | 2021 |
Aggressive large-cell neuroendocrine carcinoma of the sigmoid colon in a patient with ulcerative colitis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Neuroendocrine; Colitis, Ulcerative; Fatal Outcome; Female; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Precancerous Conditions; Risk Factors; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2017 |
Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel.
Topics: Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Male; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2018 |
[A Case of Locally Advanced Neuroendocrine Carcinoma of the Stomach Could be Curably Resected after Chemotherapy with CPT-11/CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms | 2017 |
[A Case Report of Neuroendocrine Carcinoma in the Gall Bladder Showing Recurrence Shortly after Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Female; Gallbladder Neoplasms; Humans; Irinotecan; Middle Aged; Recurrence; Time Factors | 2018 |
Acute Respiratory Failure During Systemic Chemotherapy.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cecal Neoplasms; Cisplatin; Etoposide; Fatal Outcome; Female; Humans; Irinotecan; Middle Aged; Neoplastic Cells, Circulating; Respiratory Insufficiency; Thrombotic Microangiopathies | 2019 |
[Gastric Neuroendocrine Carcinoma(NEC)Treated with CDDP plus CPT-11 Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2019 |
Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Chemoradiotherapy; Cisplatin; Female; Humans; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Rectal Neoplasms; Remission Induction; Tomography, X-Ray Computed; Topoisomerase I Inhibitors | 2019 |
Feasibility and efficacy of combined cisplatin plus irinotecan chemotherapy for gastroenteropancreatic neuroendocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged | 2013 |
[An elderly patient with large cell neuroendocrine carcinoma(LCNEC)for whom chemotherapy with irinotecan and split-dose cisplatin(CDDP)proved very effective].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Male | 2013 |
[A case of mixed adenoneuroendocrine carcinoma of the esophagogastric junction treated with neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Combinations; Esophagogastric Junction; Gastrectomy; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[Neuroendocrine gallbladder cancer treated with cisplatin plus irinotecan - a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Diagnosis, Differential; Female; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Middle Aged | 2014 |
Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome | 2014 |
[A case of disease-free, long survival in a patient with mixed adenoneuroendocrine carcinoma of the gallbladder treated with induction CDDP/CPT-11 chemotherapy and resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Female; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Middle Aged; Time Factors; Treatment Outcome | 2015 |
Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis | 2015 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Capecitabine; Carboplatin; Carcinoma, Neuroendocrine; Chemoradiotherapy; Cisplatin; Consolidation Chemotherapy; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Pelvis; Radiation Injuries; Radiodermatitis; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Rectum; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
[A Case of Esophageal Neuroendocrine Carcinoma for Which Irinotecan and Cisplatin Combination Therapy Was Effective].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Deglutition Disorders; Esophageal Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Tomography, X-Ray Computed | 2015 |
[A successful two-stage treatment with CDDP and CPT-11 for pancreatic neuroendocrine carcinoma with liver metastasis].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
[A case of early poorly-differentiated neuroendocrine carcinoma of stomach].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cell Differentiation; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2010 |
A case report of metastatic neuroendocrine carcinoma of the right adrenal gland successfully treated with chemotherapy and surgery.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2010 |
[A case of gastric large cell neuroendocrine carcinoma (LCNEC) for whom chemotherapy of CDDP+CPT-11 proved very effective].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Gastroscopy; Humans; Irinotecan; Male; Stomach Neoplasms; Tomography, X-Ray Computed | 2010 |
[A rare case of large cell neuroendocrine carcinoma of the thymus].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Fatal Outcome; Humans; Irinotecan; Male; Middle Aged; Thymus Neoplasms | 2010 |
Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma.
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Camptothecin; Carcinoma, Neuroendocrine; Cell Proliferation; Drug Carriers; Female; Flow Cytometry; Gastrointestinal Agents; Humans; Irinotecan; Liposomes; Mice; Mice, Inbred ICR; Mice, Nude; Octreotide; Receptors, Somatostatin; Thyroid Neoplasms; Tumor Cells, Cultured | 2011 |
Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Disease-Free Survival; Female; History, 17th Century; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Retrospective Studies; Stomach Neoplasms | 2011 |
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Central Nervous System Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2011 |
Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Neuroendocrine; Cell Line, Tumor; Humans; Irinotecan; Liposomes; Mice; Octreotide; Phosphorylation; Receptors, Somatostatin; Ribosomal Protein S6 Kinases, 70-kDa; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Nedaplatin and irinotecan in patients with large-cell neuroendocrine carcinoma of the lung.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds | 2012 |
Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cell Differentiation; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Retrospective Studies | 2012 |
[A case of poorly-differentiated neuroendocrine carcinoma of the ascending colon with multiple liver metastases successfully treated with cisplatin and irinotecan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cell Differentiation; Cisplatin; Colon, Ascending; Fatal Outcome; Female; Humans; Irinotecan; Liver Neoplasms; Tomography, X-Ray Computed | 2012 |
[A case of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix successfully treated by postoperative CPT-11+CDDP chemotherapy after non-curative surgery].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Neoplasm Invasiveness; Tomography, X-Ray Computed; Uterine Cervical Neoplasms | 2012 |
Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Docetaxel; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
[Neuroendocrine carcinoma of the prostate effectively treated by cisplatin and irinotecan--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 2007 |